Eliem Therapeutics (ELYM) News Today $7.39 -0.18 (-2.38%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 6 at 1:47 AM | marketbeat.comEliem Therapeutics (NASDAQ:ELYM) Shares Up 4.6%Eliem Therapeutics (NASDAQ:ELYM) Trading 4.6% HigherAugust 26, 2024 | globenewswire.comEliem Therapeutics Announces Additions to its Leadership TeamAugust 14, 2024 | globenewswire.comEliem Therapeutics Reports Second Quarter Financial ResultsJuly 26, 2024 | marketbeat.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest UpdateEliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 742,200 shares, an increase of 98.8% from the June 30th total of 373,300 shares. Based on an average trading volume of 307,600 shares, the days-to-cover ratio is presently 2.4 days. Approximately 1.3% of the shares of the company are short sold.July 24, 2024 | insidertrades.comEliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset Sells 69,005 SharesJuly 24, 2024 | insidertrades.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 60,201 Shares of StockJuly 24, 2024 | finance.yahoo.comInsider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells SharesJuly 22, 2024 | benzinga.comIQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On MondayJuly 21, 2024 | insidertrades.comValerie Morisset Sells 3,207 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) StockJuly 19, 2024 | sg.finance.yahoo.comInsider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...July 19, 2024 | finance.yahoo.comEVP, R&D AND CSO Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics Inc (ELYM)July 18, 2024 | insidertrades.comValerie Morisset Sells 42,377 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) StockJuly 16, 2024 | marketbeat.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 42,377 Shares of StockEliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) EVP Valerie Morisset sold 42,377 shares of the firm's stock in a transaction on Monday, July 15th. The shares were sold at an average price of $7.01, for a total value of $297,062.77. Following the completion of the sale, the executive vice president now owns 252,306 shares of the company's stock, valued at $1,768,665.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.July 12, 2024 | insidertrades.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 5,931 Shares of StockJuly 12, 2024 | insidertrades.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 50,000 Shares of StockJuly 11, 2024 | marketbeat.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Sees Significant Growth in Short InterestEliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 373,300 shares, an increase of 552.6% from the June 15th total of 57,200 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average trading volume of 918,600 shares, the days-to-cover ratio is presently 0.4 days.July 10, 2024 | insidertrades.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 12,342 Shares of StockJuly 4, 2024 | insidertrades.comEliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset Sells 50,000 SharesJuly 2, 2024 | insidertrades.comRa Capital Management, L.P. Acquires 13,008,546 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) StockJuly 1, 2024 | marketbeat.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Director Buys $49,952,816.64 in StockEliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) Director Ra Capital Management, L.P. acquired 13,008,546 shares of Eliem Therapeutics stock in a transaction on Thursday, June 27th. The shares were bought at an average price of $3.84 per share, for a total transaction of $49,952,816.64. Following the completion of the purchase, the director now directly owns 23,521,757 shares in the company, valued at $90,323,546.88. The purchase was disclosed in a legal filing with the SEC, which is available through this link.June 28, 2024 | globenewswire.comEliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® IndexesJune 27, 2024 | globenewswire.comEliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private PlacementJune 13, 2024 | marketbeat.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest Down 53.5% in MayEliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the target of a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 59,900 shares, a decline of 53.5% from the May 15th total of 128,800 shares. Based on an average daily trading volume, of 863,600 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.3% of the shares of the company are sold short.May 29, 2024 | marketbeat.comShort Interest in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Rises By 127.2%Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 128,800 shares, a growth of 127.2% from the April 30th total of 56,700 shares. Based on an average trading volume of 850,300 shares, the short-interest ratio is presently 0.2 days. Approximately 0.7% of the shares of the company are sold short.May 17, 2024 | benzinga.comEliem Therapeutics Stock (NASDAQ:ELYM), Earnings Estimates, EPS, and RevenueApril 25, 2024 | marketbeat.comShort Interest in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Increases By 4,453.8%Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 601,100 shares, an increase of 4,453.8% from the March 31st total of 13,200 shares. Currently, 3.3% of the company's stock are short sold. Based on an average trading volume of 665,800 shares, the short-interest ratio is currently 0.9 days.April 24, 2024 | marketbeat.comBML Capital Management LLC Boosts Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)BML Capital Management LLC boosted its position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 12.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,180,000 shares of the compApril 23, 2024 | marketbeat.comEliem Therapeutics (NASDAQ:ELYM) Trading 0.5% Higher Eliem Therapeutics (NASDAQ:ELYM) Shares Up 0.5%April 15, 2024 | prnewswire.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the FirmApril 12, 2024 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementApril 11, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODNApril 11, 2024 | finance.yahoo.comEliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines DealApril 11, 2024 | msn.comEnlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals among healthcare moversApril 11, 2024 | markets.businessinsider.comEliem Therapeutics To Buy Tenet Medicines, Plans $120 Mln Private Placement; Stock Up In Pre-marketApril 11, 2024 | businesswire.comELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to ShareholdersApril 11, 2024 | globenewswire.comEliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementApril 5, 2024 | msn.comELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023March 6, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn SituationFebruary 18, 2024 | marketbeat.comSilverarc Capital Management LLC Lowers Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)Silverarc Capital Management LLC trimmed its holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 75.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 121,110 shares of the company's stock after sellingFebruary 3, 2024 | marketbeat.comEliem Therapeutics (NASDAQ:ELYM) Shares Up 3.5%Eliem Therapeutics (NASDAQ:ELYM) Trading Up 3.5%November 19, 2023 | morningstar.comCheckpoint Therapeutics Inc CKPTNovember 15, 2023 | morningstar.comEliem Therapeutics Inc ELYMSeptember 28, 2023 | finance.yahoo.comEliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth PlansJuly 21, 2023 | finance.yahoo.comEliem (ELYM) to Explore Strategic Options, Stock Rises 6%July 21, 2023 | msn.comEliem Therapeutics’ stock soars 21% premarket after company says it may sell itselfJuly 20, 2023 | benzinga.comWhat's Happening With Eliem Therapeutics Shares Today?July 20, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Announces Plans to Explore Strategic AlternativesJuly 20, 2023 | marketwatch.comEliem Therapeutics Shares Rally Premarket on Exploration of Options >ELYMJuly 20, 2023 | markets.businessinsider.comWhy Is Eliem Therapeutics (ELYM) Stock Up 6% Today?July 20, 2023 | finance.yahoo.comEliem Therapeutics Announces Plans to Explore Strategic Alternatives Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address Say Goodbye to the US Dollar (Ad)The warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] ELYM Media Mentions By Week ELYM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELYM News Sentiment▼0.300.55▲Average Medical News Sentiment ELYM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELYM Articles This Week▼10▲ELYM Articles Average Week Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: XBiotech News Compugen News Marinus Pharmaceuticals News Cue Biopharma News Biora Therapeutics News MEI Pharma News Altimmune News COMPASS Pathways News Sage Therapeutics News Bicycle Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELYM) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.